Literature DB >> 3009125

Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer.

S Sutton, B L Lum, F M Torti.   

Abstract

Bacterial and fungal contaminants have been identified in marijuana samples and thus are a potential risk factor in the immunocompromised patient using it as an antiemetic. We describe the development of an invasive pulmonary aspergillosis in a patient using illicitly obtained marijuana as an antiemetic during combination antitumor therapy for small cell lung cancer. Although this patient had multiple risk factors implicated in the development of invasive pulmonary aspergillosis, the infectious potential of inhaled marijuana must be recognized. Further study of this potential health risk in needed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009125     DOI: 10.1177/106002808602000416

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  5 in total

Review 1.  Lung disease induced by drug addiction.

Authors:  M K Benson; A M Bentley
Journal:  Thorax       Date:  1995-11       Impact factor: 9.139

2.  Inhaled medicinal cannabis and the immunocompromised patient.

Authors:  Rosa Ruchlemer; Michal Amit-Kohn; David Raveh; Lumír Hanuš
Journal:  Support Care Cancer       Date:  2014-09-13       Impact factor: 3.603

3.  Too many mouldy joints - marijuana and chronic pulmonary aspergillosis.

Authors:  Yousef Gargani; Paul Bishop; David W Denning
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-01-14       Impact factor: 2.576

4.  Trends in Prevalence and Outcomes of Cannabis Use Among Chronic Obstructive Pulmonary Disease Hospitalizations: A Nationwide Population-Based Study 2005-2014.

Authors:  Kulothungan Gunasekaran; Dinesh C Voruganti; Mandeep Singh Rahi; Kalaimani Elango; Sathishkumar Ramalingam; Adiba Geeti; Jeff Kwon
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-15

5.  Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis.

Authors:  Arno Hazekamp
Journal:  Front Pharmacol       Date:  2016-04-27       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.